We are live on ! Find out more
IBT

International Biotechnology Trust Portfolio holdings

AUM $297M
1-Year Est. Return 17.25%
This Fund
S&P 500
This Quarter Est. Return
+4.48%
1 Year Est. Return
+17.25%
3 Year Est. Return
+11.14%
5 Year Est. Return
+79.35%
10 Year Est. Return
–
AUM
$329M
AUM Growth
-$29.9M
Cap. Flow
-$29.1M
Cap. Flow %
-8.87%
Top 10 Hldgs %
51.54%
Holding
77
New
13
Increased
17
Reduced
12
Closed
16

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$12.2M
2
APLS
Apellis Pharmaceuticals
APLS
+$8.46M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$7.07M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$6.94M
5
GILD icon
Gilead Sciences
GILD
+$6.94M

Top Sells

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$40.5M
2
ALKS icon
Alkermes
ALKS
+$16.7M
3
EXEL icon
Exelixis
EXEL
+$10.5M
4
QURE icon
uniQure
QURE
+$8.77M
5
RARE icon
Ultragenyx Pharmaceutical
RARE
+$8.53M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AMGN icon
1
Amgen
AMGN
$236B
$26M 7.92%
117,246
+26,000
+28% +$6.03M
INCY icon
2
Incyte
INCY
$25.9B
$22.3M 6.79%
358,454
+79,454
+28% +$5.31M
HRMY icon
3
Harmony Biosciences
HRMY
$2.32B
$20.1M 6.11%
570,500
– –
REGN icon
4
Regeneron Pharmaceuticals
REGN
$83.1B
$19.4M 5.91%
27,000
+15,800
+141% +$12.2M
SUPN icon
5
Supernus Pharmaceuticals
SUPN
$2.57B
$15.7M 4.79%
523,500
+100,000
+24% +$3.5M
VERA icon
6
Vera Therapeutics
VERA
$2.5B
$15.6M 4.76%
975,227
-27,030
-3% -$244K
ALNY icon
7
Alnylam Pharmaceuticals
ALNY
$31.6B
$15.5M 4.72%
81,600
+35,000
+75% +$6.94M
APLS
8
DELISTED
Apellis Pharmaceuticals
APLS
$11.8M 3.6%
129,700
+98,000
+309% +$8.46M
UTHR icon
9
United Therapeutics
UTHR
$22.7B
$11.6M 3.55%
52,759
+24,259
+85% +$5.37M
ITCI
10
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$11.2M 3.4%
176,856
-81,000
-31% -$5.05M
GILD icon
11
Gilead Sciences
GILD
$185B
$11.1M 3.39%
144,584
+87,000
+151% +$6.94M
ILMN icon
12
Illumina
ILMN
$34.3B
$9.46M 2.88%
51,914
+24,672
+91% +$4.99M
MRTX
13
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$9.39M 2.86%
260,000
+16,000
+7% +$659K
VRTX icon
14
Vertex Pharmaceuticals
VRTX
$139B
$7.39M 2.25%
21,000
-12,000
-36% -$4.04M
RVNC
15
DELISTED
Revance Therapeutics, Inc.
RVNC
$7.3M 2.22%
288,726
+105,726
+58% +$3.29M
HZNP
16
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$6.89M 2.1%
+67,000
New +$7.07M
TVTX icon
17
Travere Therapeutics
TVTX
$6.37B
$6.77M 2.06%
441,019
+300,000
+213% +$5.46M
NBIX icon
18
Neurocrine Biosciences
NBIX
$15.8B
$6.49M 1.98%
+68,877
New +$6.73M
KRTX
19
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$5.57M 1.69%
25,700
+14,700
+134% +$3.15M
AUPH icon
20
Aurinia Pharmaceuticals
AUPH
$2.19B
$5.55M 1.69%
573,530
– –
DNLI icon
21
Denali Therapeutics
DNLI
$3.95B
$5.54M 1.69%
188,000
+101,425
+117% +$2.85M
KRYS icon
22
Krystal Biotech
KRYS
$10.6B
$5.39M 1.64%
45,945
-15,055
-25% -$1.54M
BMRN icon
23
BioMarin Pharmaceuticals
BMRN
$12.6B
$5.08M 1.55%
58,656
– –
MDGL icon
24
Madrigal Pharmaceuticals
MDGL
$12.6B
$4.23M 1.29%
+18,300
New +$4.96M
AXSM icon
25
Axsome Therapeutics
AXSM
$10.8B
$4.19M 1.27%
+58,300
New +$4.3M
1
2 3 4

Similar funds

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

International Biotechnology Trust's Q2 2023 Portfolio in Review

As of Q2 2023, International Biotechnology Trust held 77 positions worth $329M, down 8.3% from $358M the previous quarter. Its ten largest holdings account for 52% of the portfolio.

International Biotechnology Trust withdrew a net $29.1M in Q2 2023, closing 16 positions and reducing 12 holdings. Its most notable exit was Seagen Inc. Common Stock, an estimated $40.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

Against the trend, International Biotechnology Trust opened a new position in Horizon Therapeutics Public Limited Company Ordinary Shares worth $6.89M.

  • International Biotechnology Trust's largest Q2 2023 buy was Horizon Therapeutics Public Limited Company Ordinary Shares: 67,000 shares worth $6.89M.
  • International Biotechnology Trust added most to Regeneron Pharmaceuticals in Q2 2023, an estimated $12.2M increase.
  • International Biotechnology Trust's biggest Q2 2023 reduction was uniQure, cutting an estimated $8.77M.
  • International Biotechnology Trust fully exited Seagen Inc. Common Stock in Q2 2023, selling an estimated $40.5M.
  • International Biotechnology Trust's ten largest holdings make up 52% of its $329M portfolio in Q2 2023.
  • International Biotechnology Trust opened 13 new positions and closed 16 in Q2 2023.
  • International Biotechnology Trust's portfolio value fell 8.3% quarter-over-quarter to $329M.

Based on International Biotechnology Trust's 13F filing for Q2 2023, filed 8 Aug 2023.